<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">Hyperglycaemia</z:e> is a risk factor for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and some sulphonylureas have anti-oxidant properties </plain></SENT>
<SENT sid="1" pm="."><plain>This study examined associations between use of sulphonylureas and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A consecutive cohort of 6103 Hong Kong Chinese patients with T2DM, free of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, was analysed using Cox models </plain></SENT>
<SENT sid="3" pm="."><plain>Sulphonylurea usage was defined as use of the drugs at or within 2.5 years before enrolment and/or during follow-up periods </plain></SENT>
<SENT sid="4" pm="."><plain>We adjusted for identified risk factors of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, use of other drugs, non-linear associations of <z:chebi fb="23" ids="18059">lipids</z:chebi> with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and probabilities of use of these drugs at different times and doses where appropriate </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: During a median of 4.91 years of follow-up, 271 developed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="5441">Glibenclamide</z:chebi>, <z:chebi fb="0" ids="31654">gliclazide</z:chebi> and glipizide were ever used in 32.5% (n = 1983), 47.8% (n = 2920) and 13.5% (n = 823) </plain></SENT>
<SENT sid="7" pm="."><plain>After adjustment for covariates, use of <z:chebi fb="0" ids="31654">gliclazide</z:chebi> and <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> was associated with reduced <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in a dose-dependent manner </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, there were interactions between <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="5441">glibenclamide</z:chebi>/glipizide use towards lower adjusted <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In T2DM, use of <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> and <z:chebi fb="0" ids="31654">gliclazide</z:chebi> may be associated with reduced <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
</text></document>